Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

LINACLOTIDE

LINACLOTIDE

Standard Dose
290MCG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview LINACLOTIDE is listed in Drugs@FDA under application 209611 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient LINACLOTIDE Form and strength CAPSULE;ORAL - 290MCG Sponsor AUROBINDO PHARMA Submission history Latest submission status date: 2023-02-07 00:00:00.

Structured Monograph

Clinical summary

Approval overview LINACLOTIDE is listed in Drugs@FDA under application 209611 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient LINACLOTIDE Form and strength CAPSULE;ORAL - 290MCG Sponsor AUROBINDO PHARMA Submission history Latest submission status date: 2023-02-07 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.